3-(phenethylthio)pyrazin-2(1H)-one | 942910-23-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 3-(phenethylthio)pyrazin-2(1H)-one
• 英文别名: 3-(2-phenylethylsulfanyl)-1H-pyrazin-2-one
• CAS: 942910-23-8
• 化学式: C₁₂H₁₂N₂OS
• 分子量: 232.306
• InChiKey: DQDPZTNRGVUGRI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(phenethylthio)pyrazin-2(1H)-one 、 1-(4-bromo-2-methylphenoxy)-2-methylpropan-2-ol 在 copper(l) iodide potassium phosphate 、 N,N'-二甲基乙二胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 以57.5%的产率得到1-(4-(2-Hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(phenethylthio)pyrazin-2(1H)-one
  参考文献：
  名称：

  NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS

  摘要：

  本申请提供了根据公式I提供的化合物，包括所有立体异构体、溶剂合物、前药和药学上可接受的形式， 其中 R 1 ，R 2 ，R 3 ，R 8 和R 9 在此定义。 此外，本申请提供了含有至少一种根据公式I的化合物和可选至少一种额外治疗剂的药物组合物。最后，本申请提供了治疗患有MCHR-1调节性疾病或紊乱的患者的方法，例如肥胖症、糖尿病、抑郁症或焦虑症，通过给予根据公式I的化��物的治疗有效剂量。

  公开号：

  US20090011994A1
• 作为产物：
  描述：

  2-Chloro-3-(2-phenylethylsulfanyl)pyrazine 在 sodium hydroxide 、 水 、 二甲基亚砜 作用下， 反应 0.5h， 以12%的产率得到3-(phenethylthio)pyrazin-2(1H)-one
  参考文献：
  名称：

  WO2007/71646

  摘要：

  公开号：

文献信息

• Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods
  申请人：Bristol-Myers Squibb Company

  公开号：US08067420B2

  公开（公告）日：2011-11-29

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1, R2, R3, R8, and R9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了公式I中的化合物，包括所有立体异构体、溶剂化物、前药和药学上可接受的形式，其中R1、R2、R3、R8和R9在此定义。此外，本申请提供了含有至少一种公式I化合物和可选的至少一种额外治疗剂的制药组合物。最后，本申请提供了通过给患有MCHR-1调节性疾病或紊乱的患者以公式I中化合物的治疗有效剂量来治疗患者的方法，例如肥胖、糖尿病、抑郁症或焦虑症。
• SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS
  申请人：Stein Philip D.

  公开号：US20110144060A1

  公开（公告）日：2011-06-16

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R 1 , R 2 , R 3 , R 8 , and R 9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了一种化合物，包括所有立体异构体、溶剂化合物、前药和其制备的药学上可接受的形式，其化学式为I式，其中R1、R2、R3、R8和R9的定义如本文所述。此外，本申请还提供了含有至少一种I式化合物和可选的至少一种其他治疗剂的药物组合物。最后，本申请提供了通过给予I式化合物的治疗有效剂量来治疗患有MCHR-1调节性疾病或疾病的患者的方法，例如肥胖症、糖尿病、抑郁症或焦虑症。
• NOVEL SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES
  申请人：Janssen Pharmaceutica N.V.

  公开号：EP1966164B1

  公开（公告）日：2013-03-06
• Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases
  申请人：Andres-Gil Jose Ignacio

  公开号：US20090012062A1

  公开（公告）日：2009-01-08

  The present invention concerns aryl and heteroaryl substituted pyrazinone derivatives having antagonistic melanin-concentrating hormone (MCH) activity, in particular MCH-1 activity according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1 . It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are useful for the prevention and/or treatment of psychiatric disorders, including but not limited to anxiety, eating disorders, mood disorders, such as bipolar disorders and depression, psychoses, such as schizophrenia, and sleeping disorders; obesity; diabetes; sexual disorders and neurological disorders.
• US8012984B2
  申请人：——

  公开号：US8012984B2

  公开（公告）日：2011-09-06